Combating opportunistic infections: coccidioidomycosis

Bibliography

• PAPPAGIANIS D: Epidemiology of coccidioidomycosis. Carr: Top. Med. Mycol. (1988) 2:199–238.
   PubMedGoogle Scholar
• ••An excellent review of the epidemiology ofcoccidioidomycosis.
   Google Scholar
• EDWARDS PQ, PALMER CE: Prevalence of sensitivity to coccidioidin, with special reference to specific and nonspecific reactions to coccidioidin and histoplasmin. Dis. Chest (1957) 31:35–60.
   PubMedGoogle Scholar
• PAPPAGIANIS D: Marked increase in cases of coccidioidomycosis in California: 1991, 1992 and 1993. Clin. Infect. Dis. (1994) 19\(Suppl. 1):S14–S18.
   Google Scholar
• AMPEL NM, MOSLEY DG, ENGLAND B, VERTZ PD, KOMATSU K, HAJJEH RA: Coccidioidomycosis in Arizona: increase in incidence from 1990 to 1995. Clin. Infect. Dis. (1998) 27(6):1528–1530.
   PubMedGoogle Scholar
• CDC: Increase in coccidioidomycosis-Arizona, 1998-2001. Moth. Mortal Wkly Rep. (2003) 52(6):109–112.
   PubMedGoogle Scholar
• LEAKE JA, MOSLEY DG, ENGLAND B et al.: Risk factors for acute symptomatic coccidioidomycosis among elderly personsin Arizona, 1996–1997.1 Infect. Dis.(2000) 181(4):1435–1440.
   Google Scholar
• FISHER MC, KOENIG GL, WHITE TJ, TAYLOR JW: Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia (2002) 94(1):73–84.
   Google Scholar
• BOWMAN BH, WHITE TJ,TAYLOR JW: Human pathogeneic fungi and their close nonpathogenic relatives. Phylogenet. Eva (1996) 6(1):89–96.
   PubMedGoogle Scholar
• SUN SH, HUPPERT M: A cytological study of morphogenesis in Coccidioides immitis. Sabouraudia (1976) 14(2):185–198.
   PubMedGoogle Scholar
• SMITH CE, BEARD RR, WHITING EG, ROSENBERGER HG: Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases. Am. J. Public Health (1946) 36:1394–1402.
   PubMed Web of Science ®Google Scholar
• •Although dated, a seminal paper describing clinical manifestations and epidemiology.
   Google Scholar
• ARSURA EL, KILGORE WB,RATNAYAKE SN: Erythema nodosum in pregnant patients with coccidioidomycosis. Clin. Infect. Dis. (1998) 27(5):1201–1203.
   PubMedGoogle Scholar
• STEVENS DA: Coccidioidomycosis. N Engl. I Med. (1995) 332(16):1077–1082.
   PubMedGoogle Scholar
• AMPEL NM: The solitary pulmonary nodule. N Engl. J. Med. (2003) 349:1575 (Letter).
   Google Scholar
• SAROSI GA, PARKER JD, DOTO IL, TOSH FE: Chronic pulmonary coccidioidomycosis. N Engl. J. Med. (1970) 283(7):325–329.
   PubMedGoogle Scholar
• BOUZA E, DREYER JS, HEWITT WL, MEYER RD: Coccidioidal meningitis. An analysis of thirty-one cases and review of the literature. Medicine (Baltimore) (1981) 60(3):139–172.
   Google Scholar
• AMPEL NM, RYAN KJ, CARRY PJ, WIEDEN MA, SCHIFMAN RB: Fungemia due to Coccidioides immitis. An analysis of 16 episodes in 15 patients and a review of the literature. Medicine (Baltimore) (1986) 65(5):312–321.
   Google Scholar
• AMPEL NM: Measurement of cellular immunity in human coccidioidomycosis. Mycopathologia (2003) (In Press).
   Google Scholar
• DERESINSKI SC, STEVENS DA: Coccidioidomycosis in compromised hosts. Experience at Stanford University Hospital. Medicine (Baltimore) (1974) 54(5):377–395.
   Google Scholar
• RUTALA PJ, SMITH JW: Coccidioidomycosis in potentially compromised hosts: the effect of immunosuppressive therapy in dissemination. Am. I Med. Sd. (1978) 275(3):283–295.
   PubMedGoogle Scholar
• FISH DG, AMPEL NM, GALGIANI IN et al.: Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) (1990) 69(6):384–391.
   Google Scholar
• AMPEL NM, DOLS CL, GALGIANI IN: Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidalendemic area. Am. I Med. (1993) 94(3):235–240.
   Google Scholar
• JONES IL, FLEMING PL,CIESIELSKI CA, HU DJ, KAPLAN JE, WARD JW: Coccidioidomycosis among persons with AIDS in the United States.I Infect. Dis. (1995) 171(4):961–966.
   Google Scholar
• WOODS CW, MCRILL C,PLIKAYTIS BDet al.: Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994–1997: incidence, risk factors, and prevention. J. Infect. Dis. (2000) 181(4):1428–1434.
   Google Scholar
• AMPEL NM: Coccidioidomycosis among persons with human immunodeficiency virus infection in the era of highly active antiretroviral therapy (HAART). Semin. Respir. Infect. (2001) 16(4):257–262.
   PubMedGoogle Scholar
• •Describes the relationship between HIV infection and coccidioidomycosis.
   Google Scholar
• AMPEL NM, KRAMER LA, LI L et al: In vitro whole-blood analysis of cellular immunity in patients with active coccidioidomycosis by using the antigen preparation T27K. Clin. Diagn. Lab. Immunol (2002) 9(5):1039–1043.
   PubMedGoogle Scholar
• COHEN IM, GALGIANI IN, POTTER D, OGDEN DA: Coccidioidomycosis in renal replacement therapy. Arch. Intern. Med. (1982) 142(3):489–494.
   PubMedGoogle Scholar
• HALL KA, SETHI GK, ROSADO LJ, MARTINEZ JD, HUSTON CL, COPELAND JG: Coccidioidomycosis and heart transplantation. I Heart Lung Transplant. (1993) 12(3):525–526.
   PubMedGoogle Scholar
• HOLT CD, WINSTON DJ, KUBAK B et al.: Coccidioidomycosis in liver transplant patients. Clin. Infect. Dis. (1997) 24(2):216–221.
   PubMedGoogle Scholar
• RILEY DK, GALGIANI IN,O'DONNELL MR, ITO II, BEATTY PG, EVANS TG: Coccidioidomycosis in bone marrow transplant recipients. Transplantation (1993) 56(6):1531–1533.
   PubMedGoogle Scholar
• LOGAN IL, BLAIR JE, GALGIANI JN: Coccidioidomycosis complicating solid organ transplantation. Semin. Respir. Infect. (2001) 16(4):251–256.
   PubMedGoogle Scholar
• KEANE J, GERSHON S, WISE RP et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl. I Med. (2001) 345(15):1098–1104.
   PubMed Web of Science ®Google Scholar
• LEE JH, SLIFMAN NR, GERSHON SK et al.: Life-threatening histoplasmosis complicating immunotherapy with tumornecrosis factor alpha antagonists infliximab and etanercept. Arthritic Rheum. (2002) 46(10):2565–2570.
   PubMed Web of Science ®Google Scholar
• BERGSTROM L, YOCUM D, AMPEL NM et al: Relative risk for symptomatic coccidioidomycosis is increased with infliximab therapy: results of a cohort study. Art& Rheum. (2003) 48\(Suppl. 9)5450 (Abstract 1126).
   Google Scholar
• FLYNN NM, HOEPRICH PD, KAWACHI MM et al.: An unusual outbreak of windborne coccidioidomycosis. N. Engl. J. Med. (1979) 301(7):358–361.
   PubMed Web of Science ®Google Scholar
• ROSENSTEIN NE, EMERY KW, WERNER SB et al: Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996. Clin. Infect. Dis. (2001) 32(5):708–715.
   PubMed Web of Science ®Google Scholar
• WACK EE, AMPEL NM, GALGIANI IN, BRONNIMANN DA: Coccidioidomycosis during pregnancy. An analysis of ten cases among 47,120 pregnancies. Chest (1988) 94(2):376–379.
   Google Scholar
• CALD WELL JW, ARSURA EL,KILGORE WB, GARCIA AL, REDDY V, JOHNSON RH: Coccidioidomycosis in pregnancy during an epidemic in California. Obstet. Cynecol (2000) 95(2):236–239.
   Google Scholar
• SMITH CE: Diagnosis of pulmonary coccidioidal infections. Calif Med. (1951) 75:385–391.
   PubMedGoogle Scholar
• PAPPAGIANIS D: Serologic studies incoccidioidomycosis. Semin. Respic Infect.(2001) 16(4):242–250.
   PubMedGoogle Scholar
• •A thorough review of the serology of coccidioidomycosis.
   Google Scholar
• SAROSI GA, LAWRENCE JP,SMITH DK, THOMAS A,HOBOHM DW, KELLEY PC: Rapid diagnostic evaluation of bronchial washings in patients with suspected coccidioidomycosis. Semin. Respic Infect. (2001) 16(4):238–241.
   PubMedGoogle Scholar
• WARNOCK DW: Mycotic agents of human disease. In: Biological Safety Principles and Practices. Fleming DO, Hunt DL (Eds), Washington, DC: ASM Press (2000):111–120.
   Google Scholar
• GALGIANI IN, CATANZARO A, CLOUD GA et al.: Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial.Mycoses Study Group. Ann. Intern. Med.(2000) 133(9):676–686.••
   Google Scholar
• ••A well-conducted study comparingfluconazole to itraconazole as a therapy for non-meningeal coccidioidomycosis.
   Google Scholar
• WINN WA: The use of amphotericin B in the treatment of coccidioidal disease. Arn. J. Med. (1959) 27:617–635.
   Google Scholar
• DRUTZ DJ: Amphotericin B in the treatment of coccidioidomycosis. Drugs (1983) 26(4):337–346.
   PubMedGoogle Scholar
• STEVENS DA: Miconazole in the treatment of coccidioidomycosis. Drugs (1983) 26(4):347–354.
   PubMedGoogle Scholar
• GALGIANI JN: Ketoconazole in the treatment of coccidioidomycosis. Drugs (1983) 26(4):355–363.
   PubMedGoogle Scholar
• CATANZARO A, FIERER J, FRIEDMAN PJ: Fluconazole in the treatment of persistent coccidioidomycosis. Chest (1990) 97(3):666–669.
   PubMed Web of Science ®Google Scholar
• CATANZARO A, GALGIANI JN, LEVINE BE et al: Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Arn. J. Med. (1995) 98(3):249–256.
   Google Scholar
• GRAYBILL JR, STEVENS DA, GALGIANI JN, DISMUKES WE, CLOUD GA: Itraconazole treatment of coccidioidomycosis. NIAID Mycoses Study Group. Arn. J. Med. (1990) 89(3):282–290.
   Google Scholar
• JEU L, PIACENTI FJ,LYAKHOVETSKIY AG, FUNG HB: Voriconazole. Clin. Ther. (2003) 25(5):1321–1381.
   PubMed Web of Science ®Google Scholar
• CORTEZ KJ, WALSH TJ, BENNETT JE: Successful treatment of coccidioidal meningitis with voriconazole. Clin. Infect. Dis. (2003) 36(12):1619–1622.
   PubMedGoogle Scholar
• LUTZ JE, CLEMONS KV, ARISTIZABAL BH, STEVENS DA: Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. (1997) 41(7):1558–1561.
   PubMedGoogle Scholar
• CATANZARO A, CLOUD G,STEVENS D et al.: Safety and tolerance of posaconazole (SCH 56592) in patients with nonmeningeal disseminated coccidioidomycosis. In: 46h Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17–20 (2002)Toronto, Ontario, Canada: American Society for Microbiology (Abstract 1417).
   Google Scholar
• SUGAR AM: Use of amphotericin B withazole antifungal drugs. What are we doing? Antimicrob. Agent Chemother. (1995) 39:1907–1912.
   PubMed Web of Science ®Google Scholar
• GONZALEZ GM, TIJERINA R, NAJ VAR LK et al.: Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob. Agents Chemother. (2001) 45(6):1854–1859.
   Google Scholar
• STEVENS DA: Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob. Agents Chemother. (2000) 44(9):2547–2548.
   PubMed Web of Science ®Google Scholar
• NAKAI T, UNO J, IKEDA F, TAWARA S, NISHIMURA K, MIYAJI M: In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob. Agents Chemother. (2003) 47(4):1376–1381.
   PubMed Web of Science ®Google Scholar
• HECTOR RE ZIMMER BL, PAPPAGIANIS D: Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob. Agents Chemother. (1990) 34(4):587–593.
   PubMedGoogle Scholar
• GALGIANI JN, AMPEL NM, CATANZARO A, JOHNSON RH, STEVENS DA, WILLIAMS PL: Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):658–661.
   PubMed Web of Science ®Google Scholar
• ••Recent clinical guidelines for themanagement of coccidioidomycosis.
   Google Scholar
• VINCENT T, GALGIANI JN, HUPPERT M, SALKIN D: The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. Clin. Infect. Dis. (1993) 16(2):247–254.
   PubMedGoogle Scholar
• EINSTEIN H, HOLEMAN CW, SANDIDGE LL, HOLDEN DH: Coccidioidal meningitis. The use of amphotericin B in treatment. Calif Med. (1961) 94(6):339–343.
   PubMedGoogle Scholar
• STEVENS DA, SHATSKY SA: Intrathecal amphotericin in the management ofcoccidioidal meningitis. Semin. Respir. Infect. (2001) 16(4):263–269.
   PubMedGoogle Scholar
• LABADIE EL, HAMILTON RH: Survival improvement in coccidioidal meningitis by high-dose intrathecal amphotericin B. Arch. Intern. Med. (1986) 146(10):2013–2018.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, SOBEL RA,WILLIAMS PL, PAPPAGIANIS D, STEVENS DA: Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob. Agents Chemother. (2002) 46(8):2420–2426.
   PubMedGoogle Scholar
• GALGIANI JN, CATANZARO A, CLOUD GA et al: Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann. Intern. Med. (1993) 119(1):28–35.
   Google Scholar
• DEWSNUP DH, GALGIANI JN, GRAYBILL JR et al.: Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann. Intern. Med. (1996) 124(3):305–310.
   Google Scholar
• PAPPAGIANIS D: Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am. Rev Respir. Dis. (1993) 148(3):656–660.
   PubMed Web of Science ®Google Scholar
• SHUBITZ L, PENG T, PERRILL R, SIMONS J, ORSBORN K,GALGIANI JN: Protection of mice against Coccidioides immitis intranasal infection by vaccination with recombinant antigen 2/PRA. Infect. Litman. (2002) 70(6):3287–3289.
   Google Scholar
• RICHARDS JO, AMPEL NM, LAKE DF: Reversal of coccidioidal anergy in vitro by dendritic cells from patients with disseminated coccidioidomycosis.Immunol (2002) 169(4):2020–2025.
   Google Scholar
• COLINO J, SNAPPER CM: Dendritic cells, new tools for vaccination. Microbes Infect. (2003) 5(4):311–319.
   PubMedGoogle Scholar